American Journal of Kidney Diseases
Volume 49, Issue 6 , Pages 736-743, June 2007

Iron Management in Nondialysis-Dependent CKD

  • Steven Fishbane, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Steven Fishbane, MD, 200 Old Country Rd, #135, Mineola, NY 11501.

SUNY at Stony Brook School of Medicine, Stony Brook; and Division of Nephrology and Hypertension, Dialysis Services, Winthrop University Hospital, Mineola, NY.

Received 19 January 2007; accepted 14 March 2007. published online 04 May 2007.

Iron deficiency has been studied extensively in patients with chronic kidney disease on hemodialysis therapy. However, few studies looked at iron treatment in the nondialysis chronic kidney disease population. Limited data suggest that iron deficiency is common in patients with chronic kidney disease with anemia; this lack of iron can hinder the effectiveness of erythropoiesis. The diagnosis of iron deficiency should involve clinical judgment, with an emphasis on clinical characteristics of the patient because of the limited amount of literature examining the interpretation of iron testing results. When iron deficiency is diagnosed in nondialysis patients with chronic kidney disease, a search must be initiated for any sources of blood loss. After addressing any blood loss, the preferred route of iron treatment must be determined. To date, no clear advantage was shown with intravenous versus oral administration in nondialysis patients, as shown in the hemodialysis setting. Thus, oral iron therapy may be a more reasonable option unless oral therapy previously failed. Additional research is needed to support evidence-based guidelines for the treatment of iron deficiency in the nondialysis chronic kidney disease population because this population differs from hemodialysis patients in the decreased extent of blood loss.

Index Words: Chronic kidney disease, anemia, iron deficiency, erythropoiesis-stimulating proteins

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Support: Research funding was provided by Amgen Inc, Ortho Biotech Products LP, Roche, and Watson Pharmaceuticals Inc. Potential conflicts of interest: Advisory Boards: Amgen Inc, Ortho Biotech Products LP, Roche, and Watson Pharmaceuticals Inc.Originally published online as doi:10.1053/j.ajkd.2007.03.007 on May 3, 2007.

PII: S0272-6386(07)00641-5

doi:10.1053/j.ajkd.2007.03.007

American Journal of Kidney Diseases
Volume 49, Issue 6 , Pages 736-743, June 2007